Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Agios Pharmaceuticals (AGIO) over the last 3 years, with Q3 2021 value amounting to $2.4 million.

  • Agios Pharmaceuticals' Amortization of Deferred Charges rose 500.89% to $2.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $9.4 million, marking a year-over-year increase of 566.31%. This contributed to the annual value of $8.5 million for FY2019, which is N/A changed from last year.
  • Agios Pharmaceuticals' Amortization of Deferred Charges amounted to $2.4 million in Q3 2021, which was up 500.89% from $2.3 million recorded in Q2 2021.
  • Agios Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $2.4 million for Q1 2021, and its period low was $2.1 million during Q1 2019.
  • Over the past 3 years, Agios Pharmaceuticals' median Amortization of Deferred Charges value was $2.2 million (recorded in 2020), while the average stood at $2.2 million.
  • Examining YoY changes over the last 5 years, Agios Pharmaceuticals' Amortization of Deferred Charges showed a top increase of 971.4% in 2021 and a maximum decrease of 497.31% in 2021.
  • Agios Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $2.2 million in 2019, then rose by 2.97% to $2.3 million in 2020, then increased by 5.01% to $2.4 million in 2021.
  • Its Amortization of Deferred Charges stands at $2.4 million for Q3 2021, versus $2.3 million for Q2 2021 and $2.4 million for Q1 2021.